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Abstract 
 
 
Introduction: There is a presumption that neurocognition is commonly impaired in chronic 
methadone exposed individuals (CM) when compared with healthy controls (HP). 
Additionally, it remains unclear if short term (< 1 year) abstinence (AP) is associated with an 
altered cognitive profile when compared with CM. Method: A random effect model 
approach was used on data assembled into the Comprehensive Meta-Analysis programme. 
Cohen’s d effect sizes and a significance levels of p<0.01 were calculated for each domain. 
Results: Data from a total cohort of 1063 CM, 412 AP and 879 HP participants, from 23 
independent studies indicate global impairments in neurocognitive function in CM relative 
to HP participants. The smaller body of evidence comparing CM to AP participants is 
inconclusive. Conclusion: Methodological issues such as small sample sizes, heterogeneity 
and poor quality limited the interpretation of the results and does not address whether the 
observed impairments reflect co-morbid functioning, methadone-related sedation and/or 
other factors. Only higher quality longitudinal studies will permit confident interpretation of 
the results observed in this meta-analysis. 
 
 
Keywords: Opioid Dependence; Cognitive Impairments; Methadone; Abstinence; Meta-
analysis 
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Introduction  
Replacement prescribing with methadone represents the primary pharmacotherapeutic  
strategy for the treatment for opioid dependency in the United Kingdom and many other 
countries. Its use is supported by a largely observationally derived evidence base which 
suggests that methadone prescription can be helpful in delivering several positive outcomes 
in treatment-seeking populations (Fullerton et al., 2013; Connock et al., 2007). For example, 
carefully prescribed and adequately supported methadone prescribing is associated with 
notable harm reduction outcomes in opioid dependent patients (Scottish Government., 
2007; Department of Health., 2007). It is also associated with reduced mortality and 
improved quality of life (Connock et al., 2007). The duration and dosage of methadone 
prescription are also thought to be relevant factors in these positive treatment outcomes 
(Farrell et al., 1994; Van Beusekom & Iguchi., 2001; Faggiano et al., 2007).  
 
There is, however, a widespread and general presumption that neuropsychological 
performance is commonly impaired in patients treated with methadone, possibly as a direct 
pharmacological consequence of this treatment (Darke et al., 2000). This possibility is one 
key justification cited for striving to limit the duration of methadone treatment of opioid 
dependence (Castle Craig., 2016).  Several neuropsychological studies of populations 
chronically exposed to methadone – typically formerly illicit opiate using and opioid 
dependent patients - have identified impairments in aspects of executive functioning and 
memory. These have included specifically impairments in cognitive flexibility (Darke et al., 
2000; Pirastu et al., 2006), strategic planning (Ersche et al., 2006; Ornstein et al., 2000) and 
decision making (Prosser et al., 2006). Other studies, however, have reported no clear 
impairments when comparing the performance of healthy controls with that of short term 
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(less than 1 year) abstinent former opiate users or methadone patients (Lombardo et al., 
1976; Rotherham- Fuller et al., 2004). Thus, it remains unclear if short term exposure to 
methadone or subsequent abstinence from methadone is associated with an improved 
cognitive profile when compared with patients currently in receipt of methadone. 
We have recently reported a systematic review and meta-analysis of observational studies 
of opioid exposure and neurocognitive function which found that chronic opioid exposure 
was associated with impaired cognitive impulsivity, cognitive flexibility and working 
memory. The magnitude of effect size across these cognitive domains was, by convention, 
medium. 
 
In the present review we sought to determine the strength and consistency of reported 
evidence for neuropsychological impairments in patients exposed to chronic methadone 
(CM) as part of a MMT programme when compared with (a) opioid naïve / healthy 
participants (HP) and also with (b) former MMT patients who met the criteria to be 
described as  previously opioid dependent but now abstinent for a period of at least one 
month (AP) using a quantitative synthesis of the existing primary literature (Wolf., 1986; 
Borenstein et al., 2009). We used the same methods and range of neuropsychological 
domains as reported in our previous review and meta-analysis which explored impairments 
associated with chronic opioid misuse (Baldacchino et al., 2012). 
 
Two broad questions were formulated to guide our analysis. First, does the existing 
literature provide reliable evidence for neuropsychological impairment in patients exposed 
to chronic methadone as part of a MMT programme? Second, if present, which 
neuropsychological domains are implicated when comparing methadone patients with 
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either (a) opioid naïve / healthy participants (HP) or with (b) former MMT patients who met 
criteria to be described as previously opioid dependent but now abstinent for a period of at 
least one month (range 1-12months)?  
 
Method 
Inclusion and Exclusion Criteria 
Relevant literature was identified and reviewed according to the Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) guidelines (Stroup et al., 2012) and the 
Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines 
(Liberati et al., 2009).  
 
For inclusion, studies had to report on participants aged 18 years or older. All treatment-
seeking, methadone-exposed participants had to meet DSM-IV criteria for opioid 
dependence (APA., 1994) of more than six months duration. All studies reporting any 
experimental or quasi-experimental study methods were included. Also, included studies 
had to report evidence that objective biochemical measures (e.g. urine samples) were 
collected from all study participants to confirm either a history of recent opioid intake or to 
confirm the absence of any other illicit drugs throughout the study period (Spitzer & Robins., 
1978; APA., 1952; APA., 1987; WHO., 1977; WHO., 1993). Studies were excluded if they 
either recruited participants who were tested when taking different types of licit and illicit 
opioids (polydrug use), or were not prescribed methadone. Studies were also excluded if 
they were conducted in non-substance misuse treatment settings (e.g. chronic pain and 
psychiatric settings). Moreover, all studies that compared methadone patients to individuals 
taking buprenorphine and/or where there was co-occurring benzodiazepine, psycho-
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stimulant or alcohol dependence, a history of psychosis, post-traumatic stress disorder 
(PTSD), neurological and neurodevelopmental disorders, borderline or psychopathic 
personality disorders and/or head injury were also excluded. Additionally, other studies that 
reported statistical significance of any effects but did not provide actual values permitting 
effect size calculations were excluded. 
 
Search Strategy 
Electronic and hand search methods were employed.  The electronic search was performed 
using the following databases: PUBMED (1975 to 30th Dec 2014), EMBASE (1980 to 30th Jan 
2016), Project CORK, PsychINFO (1980 to 30th Jan 2016) and MEDLINE (1975 to 30th Jan 
2016). No language constraints were applied. Subject headings included ‘chronic and/or 
repeated drug use/abuse/misuse/dependence/addiction and/or chronic opiate 
use/abuse/misuse/dependence/addiction and/or methadone/opioid treatment AND 
neuropsychological deficits/impairments and/or cognitive deficits/impairments’. The term 
neurocognitive/neuropsychological was then replaced with a succession of terms describing 
cognitive domains. These were: ‘verbal working memory tests, episodic memory tests, 
visuospatial working memory tests, verbal fluency tests, executive function tests, digit 
symbol substitution tests, intelligence, reaction time, attention measures’. The term 
neurocognitive/neuropsychological was also subsequently replaced with a succession of 
terms describing names of a list of cognitive tests and using wild cards.  
 
Three of the authors (AB, AM and KM) independently reviewed all abstracts identified from 
the electronic search and selected the studies meeting inclusion criteria. A snowballing 
technique was employed such that the reference list of identified articles was screened for 
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suitable studies. A hand search of 21 mental health / addiction / psychiatric journals for the 
years 2004-2016 was completed. These were: The American Journal of Psychiatry, Archives 
of General Psychiatry, British Journal of Psychiatry, Journal of Nervous and Mental Disease, 
Psychiatry Research, Psychological Medicine, Psychopharmacology, Neuropsychology 
Review, Neuropsychopharmacology, Archives of Clinical Neuropsychology, Experimental and 
Clinical Psychopharmacology, Journal of Clinical Psychopharmacology, Journal of 
Psychopharmacology, Neuropsychologia, Human Psychopharmacology, Brain and Cognition, 
Drug and Alcohol Dependence, Addictive Behaviours, Addiction, European Addiction 
Research and The Lancet. 
 
A heuristic (trial and error) method was derived to systematically analyse data across 
heterogenous research designs. For the present analysis, if more than one control group 
was reported in a given paper, the most appropriate comparison (i.e. chronic methadone 
users compared to either healthy controls and/or abstinent groups) was made. If multiple 
occasions of testing were reported in a given study, such as to address practice effects or as 
a follow up study, only the data derived from the first assessment was used.  
 
Data Analysis and Study Detail 
Standard meta-analytic techniques were employed for this review (Cooper & Hodges., 1984; 
Rosenthal., 1995). Magnitude was indexed with the effect size d to reflect the degree to 
which the dependent variable was present in the sample group or the degree to which the 
null hypothesis was false (Cohen., 1988). In mathematical terms d was the difference 
between two group means standardised via pooled standard deviation units. Effect sizes 
(i.e. Cohen’s d statistics) were calculated for each neuropsychological test and then adjusted 
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for sampling bias (Hunter & Schmidt., 1990). A value above 0.80 was considered as a large 
effect, with less than 0.50 as a small effect and 0.50-0.79 as intermediate (Cohen., 1992; 
Hedges & Olkin., 1985). Formulae were appropriately adjusted so that all derived statistics 
informally represented the same direction; that is the same polarity of performance when 
comparing groups. Negative scores in this review always represented impaired performance 
on the part of the chronic opiate user group. A significance level of p<0.01 (two tailed) was 
used. 
All relevant test variables were coded into one of seven neuropsychological domains listed 
under five headings (Ersche & Sahakian., 2007); 
1. Impulsivity was divided into 3 domains of Cognitive, Motor and Non-Planning 
Impulsivity (Ersche & Sahakian., 2007; Baumeister & Scher.,1988; Cooper et al., 
2003; Kirby et al., 1999; Owen., 1997)  
2. Cognitive Flexibility (Reynolds et al., 2006)  
3. Attention and Information Processing 
4. Short Term Memory (Grattan & Eslinger., 1989; Baddeley & Logie., 1999)  
5. Longer Term Memory 
 
In keeping with recommendations on meta-analytical research in neuropsychology, previous 
factor-analyses of cognitive measures in addictions informed the placement of each 
measure into the aforementioned domains (Passolunghi & Mammarella., 2010; Goldstein et 
al., 2004). This approach provided an objective alternative to the arbitrary grouping of 
neuropsychological variables on the basis of face validity or other weak and unconfirmed 
notions (Bates et al., 2002). Unfortunately, the factor-analytical studies to date do not 
encompass all of the neuropsychological measures that were encountered in this 
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comprehensive systematic review. As a result we also relied on the classification used by the 
authors of a given study (Demakis., 2006).  
 
INSERT TABLES 1 & 2: Neuropsychological domains 
 
Tests for the presence and degree of heterogeneity were conducted using the Q statistic  
(Hedges & Olkin., 1992)  and I² index (Ersche et al., 2005) respectively. A value of 0% to the 
I2 index indicated no observed heterogeneity, whereas as value of 75% or above indicated 
high heterogeneity. However, quantification of heterogeneity was only one component of a 
wider investigation of variability across studies; the most important of these were diversity 
in clinical and methodological domains and the observed degree of inconsistency across 
studies with regards to the direction of effects (Huedo-Medina et al., 2006). As different 
scales were sometimes used by different studies, Standardised Mean Difference (SMD) 
effect-size estimates were routinely calculated. Random effects models were applied 
(Higgins et al., 2003; Hedges & Verea., 1998).  
 
Eligible research studies comprising a common dependent variable, as well as test statistics 
that could be transformed into effect sizes, were systematically sampled and surveyed. 
Individual study results (typically means and standard deviations from each group) and 
relevant moderator variables considered as relevant by previous reviews (chronicity of 
opioid use, dosage of methadone, quality of the study, period of abstinence, Intelligence 
Quotient (IQ), age and educational status of the populations studied) were employed as 
moderators during this review.  
 
  
 11 
For continuous moderator variables (dosage of methadone, chronicity of opioid use, period 
of abstinence less or equal to one year duration, age, IQ, and educational status) we 
attempted to conduct a meta-regression to test whether there were significant relationships 
between each of these moderators and the effect size. Meta-regression was only conducted 
in neuropsychological domains in which more than 10 studies were available.  
 
The risk of publication bias was assessed informally by visual inspection of funnel plots and 
formally by its statistical analogue, Fail Safe N, according to Orwin (1983).  
The data were abstracted, quantified, coded and assembled into a database run by 
Comprehensive Meta-Analysis Version 2 (CMA., Bio-Englewood, New Jersey, US).  
 
Assessment of Study Quality 
All data were extracted by two reviewers (AB and MA) and checked by another two 
reviewers (KM and GH). Discrepancies were resolved by referral to the original studies. If 
necessary, arbitration was conducted by a third reviewer (DB). Duplicate publications were 
actively screened for and, when retrieved, the latest and most complete data set was used. 
The Effective Public Health Practice Project (EPHPP) quality assessment checklist was also 
used (Armijo-Olivo et al., 2012).  
 
Results  
Studies Selected and Populations Studied 
Electronic and hand searching yielded 1348 references. In total, 303 articles were retrieved 
for further assessment following the exclusion of non-relevant or ineligible studies. There 
were 176 studies that compared current chronic methadone exposed patients (CM) with 
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either abstinent individuals (AP) and/or healthy participants (HP). From these studies, a 
further 152 were excluded because, on detailed inspection, they did not satisfy the inclusion 
criteria (e.g. included polydrug users, no data presented, did not attend substance misuse 
services, no healthy or abstinent comparators, etc.) (Figure 1).  
 
INSERT FIGURE 1 
 
Of the 28 articles identified, 21 compared chronic methadone (CM) exposed patients with 
healthy and non-substance using individuals (HP) and 7 studies compared chronic 
methadone (CM) patients with short term abstinent, but previously opioid-dependent 
individuals (AP). Overall, there were 23 independent studies (Darke et al., 2000; Pirastu et 
al., 2006; Ersche et al., 2006., Ornstein et al., 2000; Prosser et al., 2006; Rotherham-Fuller et 
al., 2004; Ersche et al., 2005; Schindler et al., 2004; Mintzer et al., 2005; Soyka et al., 2008; 
Yates., 2009; Fadardi & Ziaee., 2010; Yin et al., 2012; Lin et al., 2012; McDonald et al., 2012; 
Anderson et al., 2013; Liao et al., 2014; Baldacchino et al., 2014; Clark et al., 2006; Gupta et 
al., 2014; Wang et al., 2014; Gritz et al, 1975; Davis et al., 2002) and from these, 5 studies 
used both healthy and abstinent groups as comparators to a methadone cohort (Prosser et 
al., 2006; Schindler et al., 2004; Lin et al., 2012; Anderson et al., 2013; Tolomeo et al, 2016). 
All studies reported from urban settings. Two studies (Mintzer et al., 2005; McDonald et al., 
2012) were longitudinal in design, with the remainder (21 studies) being cross sectional, 
observational studies. In terms of quality assessment, two recent studies were appraised as 
strong (Liao et al., 2014; Tolomeo et al, 2016), 19 studies appraised as moderate and two 
studies appraised as weak (Wang et al., 2014; Gritz et al., 1975).  
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Chronic Methadone (CM) and Healthy Participant (HP) Comparisons 
Twenty one studies described a total number of 884 CM compared with 879 HP participants. 
The mean age for the CM group was 36.9 years compared to 32.9 years for the HP group. 
Mean duration of opioid use was 10.3 years with a mean duration of methadone exposure 
of 3.2 years (n=18) in the CM group. The mean daily methadone dose was 61.1 mg (n=20). 
One study (Gupta et al., 2014) did not record daily methadone dose (Table 3a). 
 
Chronic Methadone (CM) and Abstinent Participant (AP) Comparisons 
Seven studies described a total number of 279 CM compared with 412 AP participants. The 
mean age for the CM group was 35.6 years compared to 35.1 years for the AP group. Mean 
duration of opioid use for the CM group was 14.1 years compared to 11.2 years for the AP 
group. The mean daily methadone dose was 61.8 mg, with an overall mean period of 
abstinence of 0.5 years (6 months) (Table 3b). 
 
 INSERT TABLES 3a & 3b: Specific characteristics of selected studies. 
 
Pooled Effect Sizes 
There were 14 effect size estimations possible from the selected studies. Analysis of 
homogeneity (Q and I2) within each neuropsychological domain tested, revealed that the 
assumption of homogeneity could not be met. Therefore, a random effects model was 
applied for all analyses 
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(1) Chronic Methadone (CM) Exposure and Healthy Participant (HP) Comparisons (Table 4a). 
For cognitive impulsivity data derived from a total of 7 studies, including 214 CM and 185 HP 
participants were pooled to reveal an effect size of 0.89 in favour of the HP participants 
being less impulsive (Z = 2.8, p<0.006) (Figure 2). For motor impulsivity a total of 9 studies, 
including 490 CM and 448 HP participants , were pooled to reveal an effect size of 0.41, 
again in favour of superior performance (less impulsivity) in the HP (Z = 4.5, p<0.001) (Figure 
3). For non-planning impulsivity a total of 7 studies, including 293  CM and 230 HP 
participants, were pooled to reveal an effect size of 1.38 in favour of a superior performance 
(less impulsive) in the HP group (Z = 3.1, p<0.002) (Figure 4). For cognitive flexibility a total 
of 12 studies, including 557 CM and 532 HP participants, were pooled to reveal an effect size 
of 0.464 in favour of a superior performance (greater flexibility) in the HP group (Z = 6.4, 
p<0.001) (Figure 5).For measures of attention a total of 8 studies, including 467 CM and 418 
HP participants, were pooled to reveal an effect size of 0.71 in favour of a superior 
performance in the HP group (Z = 3.5, p<0.001) (Figure 6). For short term memory a total of 
12 studies, including 556 CM and 524 HP participants, were pooled to reveal an effect size of 
0.67 in favour of a superior performance in the HP group (Z = 5.8, p<0.001) (Figure 7). For 
longer term memory a total of 9 studies, including 481 CM and 449 HP participants , were 
pooled to reveal an effect size of 0.68 in favour of superior performance in the HP group (Z = 
3.4, p<0.001) (Figure 8). 
 
INSERT FIGURES 2-8: Forest Plots 
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INSERT TABLE 4a: Pooled effect sizes for individual neuropsychological domains in chronic 
methadone exposed (CM) patients compared to opioid naïve healthy participants (HP) 
 
(2) Chronic Methadone (CM) and Short Term Abstinent Participant (AP) Comparisons (Table 
4b). 
For cognitive impulsivity only 2 studies were available for analysis and included 66 CM and 
48 AP participants. A non-significant pooled effect size estimate of 0.34 in favour of superior 
performance in the AP group (Z = 1.7, p=0.08) was found. Supplementary material is 
available to the reader online (SFigure1). For motor impulsivity a total of 3 studies, including 
112 CM and 311 AP participants, were pooled to reveal an estimated effect size of 0.14 
(non-significant) in favour of a superior performance in the AP group (Z = 1.2, p=0.21). 
Supplementary material is available to the reader online (SFigure2). For non-planning 
impulsivity 2 studies, including 142 CM and 78 AP participants, were pooled to reveal an 
effect size of 0.75 (non-significant) in favour of the AP group (Z =1.3, p=0.21). 
Supplementary material is available to the reader online (SFigure3). For cognitive flexibility a 
total of 5 studies, including 240 CM and 378 AP participants were pooled to reveal an effect 
size of 1.12 (non-significant) in favour of AP (Z = 2.6, p=0.01) (Figure 9).For measures of 
attention a total of 4 studies, including 137 CM and 96 AP participants , were pooled to 
reveal an effect size of 0.70 (non-significant) in favour of AP (Z =2.4, p=0.01) (Figure 10). For 
short term memory a total of 5 studies, including 166 CM and 123 AP participants were 
pooled to reveal an effect size of 0.38 in favour of AP (Z = 2.8, p<0.01) (Figure 11). For long 
term memory a total of 4 studies, including 137 CM and 96 AP participants, were pooled to 
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reveal an effect size of 0.35 in favour of AP (Z = 2.0, p=0.04) (Figure 12). This effect size was 
deemed non-significant using the criteria outlined in the methods section. 
 
INSERT FIGURES 9-12: Forest Plots 
TABLE 4b: Pooled effect sizes of individual neuropsychological domains between 
methadone exposed (CM) patients compared to the former MMT, but abstinent (AP) at 
time of testing group 
 
Subgroup Analysis: Meta-Regression 
There were not enough studies to report significant relationships between continuous 
moderator variables (dosage of methadone, chronicity of opioid use, period of abstinence 
less or equal to one year duration, age, IQ, and educational status) and most 
neuropsychological domains in both CM and AP groups to justify utilising meta-regression 
methodology. We were limited in reporting the Z value and associated p value in cognitive 
flexibility and short term memory domains for one continuous moderator (age) from the 
studies comparing CM with HP participants. It identified a non-significant effect in cognitive 
flexibility (Slope Z= -0.102, p=0.92) and short term memory (Slope Z= -0.741, p=0.46) (Tables 
5a and 5b) with older CM participants exhibiting greater cognitive impairment when 
compared with their younger peers. 
 
  
 17 
INSERT TABLES 5a and 5b: Subgroup Analysis: Meta-Regression of chronic methadone 
exposed patients by age with respect to (a) Cognitive Flexibility and (b) Short Term 
Memory. 
 
Discussion 
Key Findings 
In this quantitative review of the literature of neuropsychological functioning and chronic 
methadone exposure, our meta-analysis suggests that that a broad range of functional 
domains appear to be impaired in methadone-exposed populations compared with opioid 
naïve, healthy controls. There was also some inconclusive evidence that the impairments 
exhibited by the CM participants were greater than those exhibited by those in the AP 
group. . This stands in contrast to the differential patterns of impairment observed in an 
earlier, comparable, meta-analysis which explored the neuropsychological consequences of 
chronic opioid use (Baldacchino et al., 2012) where the only cognitive domains with 
evidence of impairment were those of verbal working memory, cognitive impulsivity and 
cognitive flexibility. There are several potential explanations for this discrepancy that 
include ascertainment and sampling bias, the heterogenous nature of different opioids in 
their cellular and molecular effects resulting in subtle pharmacological differences in 
activity, potency, effectiveness, tolerability,  neurotoxicity and neuropsychological 
impairments (Baldacchino et al., 2014).  
 
The available data, although purely cross sectional in nature, also suggest that these 
impairments may largely be detectable for, at least, the first year of abstinence. The only 
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neuropsychological domain within which there was no clear and consistent evidence of 
comparable impairment within the abstinent participants was that of short term memory. It 
is possible that abstinence may be associated with amelioration of the deficits observed in 
the CM participants. However, this apparent difference could also be explained by simple 
sampling and ascertainment bias. The present data cannot attest to whether or not opioid 
associated impairments recover after longer periods of abstinence (Holst & Schilt., 2011). 
 
Strengths and Limitations 
To minimise the potential confounding effects of other influences upon neuropsychological 
performance in study populations, we applied strict inclusion criteria. Specifically, we 
wished to minimise the potential impact of co-morbid non-opioid substance use and abuse, 
particularly alcohol. However, within such a meta-analysis, it is not possible to develop high 
levels of confidence that any selection criteria will remove the potential cumulative 
neuropsychological effects of a lifelong career of using different types of drugs and/or 
neuropsychological or neuropsychiatric precursors that might have predisposed the studied 
populations to substance misuse. Only high quality longitudinal studies can address this 
question. 
 
Methodological problems within the primary studies limit the interpretation of the results 
from this meta-analysis. For example, Tables 3a and 3b clearly describe very heterogenous 
study populations. Inevitably, study recruitment processes create a selection bias towards 
the ‘treatment seeking’ and more highly motivated individuals within substance misuse 
treatment populations (Ersche et al., 2006) and those with the greatest cognitive 
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impairments may be less likely to be included in any studies. As such, the magnitude of any 
effects associated with MMT may be an underestimate. With uncontrolled, opportunistic 
sampling in populations generating small individual study sample sizes, this will inevitably 
limit the representativeness and sensitivity of the data generated. Uniformity of group 
selection becomes relevant if one needs to analyse further significant correlations between 
residual neuropsychological effects and lifelong and current conditions (Baldacchino et al., 
2012). Studies included in this meta-analysis provided relevant information on past medical, 
neurological and psychiatric history, including history of head trauma, but did not provide 
other potentially critical information such as neurodevelopmental history and information 
on prior episodes of non-fatal overdose.  
 
There is uncertainty whether any pattern of impairments associated with concurrent 
methadone treatment might be caused by the drug itself, or whether these may have been 
pre-existing impairments that may also contribute to vulnerability to opioid abuse. 
Dissociating pre-existing impairments from pharmacologically induced changes requires a 
particular experimental design and such studies were not identified in this systematic 
review.  Similarly, although a comparison of concurrent methadone treated patients with 
former patients who were abstinent at time of testing has the potential to differentiate 
direct pharmacologically-associated effects with non-pharmacological ones, this remains a 
weak method for addressing these questions. A meta-regression could, in theory, have 
established the extent to which moderators (such as methadone dosage, years of schooling, 
length of opioid dependence) could have influenced the results. Unfortunately, there were 
insufficient numbers of studies to reliably perform such comprehensive analyses. This would 
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only be possible if more studies record detailed information of these continuous moderator 
variables. 
 
Interpretation of the cognitive impairments in the methadone treated population need to 
take into consideration the any acute sedative effects of the drug which may exaggerate the 
global impairments observed when this group are compared with healthy controls 
(Battistella et al., 2012; Franken et al., 2003). Curran et al (2001), for example, found that a 
single dose of methadone could induce episodic memory impairments on a task of delayed 
prose recall, although attention and comprehension were not affected. Methadone can also 
magnify the effects of sedatives and tranquilizers (Ghoneim., 2004). Since the abstinent 
group exhibited similar impairments in cognitive impulsivity and flexibility to those seen in 
the methadone group it would seem reasonable to suggest that the sedative effects of the 
drug do not play a significant part in the cognitive profile of methadone users. However this 
meta-analysis did not compare abstinent groups with healthy controls due to the absence of 
relevant data. This limits our understanding of any effects that sedation especially 
methadone dosages has on cognitive impairment. Future neurocognitive studies on should 
also preferably test participants during the first two hours after ingestion of methadone 
before serum methadone levels peak (Dyer et al., 1999; Mitchell et al., 2003; Ekblom et al., 
1993).  
 
In summary, the data presented in this analysis are based on a few cross sectional studies of 
mixed methodological quality. Therefore, among the features that must be considered in 
future studies in order to improve the methodological rigour and to maximise interpretation 
of the research in this field include: 
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1. Conducting well controlled high quality longitudinal studies of adequate sample size  
2. Conducting serial analyses of drug metabolites or utilising newer technology such as 
a hair analysis which have been shown to provide more definitive information about 
patterns of use 
3. Using ecologically validated neuropsychological tests   
4. Recording detailed information on continuous moderator variables such as dosage of 
methadone, chronicity of opioid use, period of abstinence less or equal to one year 
duration, age, IQ, and educational status 
5. Using latent variable analytic techniques that are designed to examine average 
effects and individual differences in tandem 
Clinical Relevance 
Bezeau & Graves, (2001) considered that, to assume the clinical usefulness of the study, it 
would be necessary for both populations (in this case, methadone users and controls) to be 
separated by at least 0.80 typical deviations in the variable measured (Bezeau & Graves., 
2001). The only effect sizes that exceeded 0.8 were cognitive and non-planning impulsivity 
when compared between chronic methadone users and healthy controls. The authors, 
however, feel justified in proposing that the neuropsychological impairments observed in 
this meta-analysis, although statistically significant, are still inconclusive for clinicians to 
justify changing current practice with regard to methadone treatment for opioid 
dependence. 
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Conclusion 
Available data support the contention that there is broad neuropsychological impairment, 
across many domains, in patients receiving MMT when compared with opioid naïve, healthy 
controls.  It is unclear, however, if this is related to opioid dependence, methadone 
exposure or a global sedative effect on performance. Additionally, there is indicative 
evidence of comparable impairment in short term abstinent, former methadone treated 
patients. However, the number of studies available for analysis was small, limiting the 
capacity for sensitive analyses and diminishing confidence in the representativeness and 
robustness of the results generated. It remains unclear if the impairments noted in MMT 
populations persist into periods of abstinence and further studies will be required to 
determine this. Prospective evaluation of neuropsychological functioning in well-designed 
longitudinal studies will be required to determine whether neuropsychological impairments 
are attributable to biological vulnerability, physical and mental co-morbidities, non-specific 
aspects of drug misuse, exposure to opioid drugs or to non-specific sedative effects.  
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Figures. 
Figure 1: Neuropsychological Consequences of Chronic Methadone Use: 
Quality of reporting of meta-analysis (QUOROM): 1975-2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relevant articles using study selection keywords, 
reference lists and manual search of journals:  
                                       N= 1348 
 Animal studies: N=248  
Conceptual/theoretical reviews rather than empirical 
studies: N=120 
Other studies not relevant to search: N=797 
 
 
Studies examined for 
inclusion/exclusion criteria: N= 303  Studies on individuals < 18 yrs old: N=23 
 Withdrawal effect studies: N= 13 
 Acute/sub-acute effects  of methadone studies 
(less than 3 months):  N=91 
Studies on adult patients with chronic opioid 
use/dependence & neuropsychological deficits 
as in inclusion criteria:  N= 176 
 Not enough data available to calculate effect 
size: N=18 
 Articles did not perform neuropsychological 
tests: N=21 
 Polydrug population: N=28 
 Successive reports using the same cohorts: N=9 
 
Studies included: N=100                        
COHORT B: Studies comparing chronic 
methadone cohorts with short term (< 1 
year) abstinent opioid users: N=7 
 
 Attending non substance use services: N=20 
 Studies also included heroin and buprenorphine 
within opioid dependent population when 
compared  with healthy controls: N=14 
 No healthy controls and/or abstinent groups as 
comparator: N=39 
 Abstinence period > 1 year N=3 
 
COHORT A: Studies comparing chronic methadone 
cohorts with healthy controls: N=21 
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Figure 2 
Study name Outcome Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Tolomeo et al 2016 CGT risk taking 0.000 0.202 0.041 -0.396 0.396 0.000 1.000
Clark et al 2006 BIS total 0.699 0.259 0.067 0.191 1.207 2.699 0.007
Ersche et al 2005 CGT overall proportion of choices for likely option 0.250 0.273 0.075 -0.286 0.786 0.915 0.360
Mintzer 2005 GT net score 0.307 0.323 0.104 -0.326 0.941 0.952 0.341
Pirastu 2006 GT net scores 3.126 0.420 0.177 2.302 3.950 7.436 0.000
Rotheram-Fuller 2004 GT net score 1.500 0.534 0.285 0.454 2.546 2.812 0.005
Yin et al 2012 IGT net score 0.818 0.246 0.061 0.335 1.301 3.322 0.001
0.893 0.324 0.105 0.258 1.528 2.757 0.006
-4.00 -2.00 0.00 2.00 4.00
Favours Methadone Favours Healthy Control
Cognitive Impulsivity: Chronic Methadone Use vs Healthy Control
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Figure 3 
Study name Outcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Baldacchino et al 2014AGN total commission errors0.720 0.273 0.075 0.185 1.256 2.635 0.008
Clark et al 2006 BIS motor 0.243 0.253 0.064 -0.252 0.739 0.962 0.336
Fadardi et al 2010 ST interference score 0.701 0.187 0.035 0.335 1.067 3.750 0.000
Gupta et al 2014 ST interference score 0.403 0.102 0.010 0.203 0.602 3.951 0.000
Liao et al 2014 SSRT post errors slowing 0.034 0.138 0.019 -0.237 0.306 0.246 0.805
Mintzer et al 2005 ST correct responses 0.235 0.322 0.104 -0.396 0.867 0.730 0.465
Prosser et al 2006 ST interference score 0.655 0.270 0.073 0.127 1.183 2.430 0.015
Wang et al 2014 ST interference colour % 0.727 0.275 0.076 0.187 1.266 2.638 0.008
Yates et al 2009 ST interference score 0.265 0.237 0.056 -0.200 0.729 1.116 0.264
0.412 0.091 0.008 0.232 0.591 4.501 0.000
-2.00 -1.00 0.00 1.00 2.00
Favours Methadone Favours Healthy Control
Motor Impulsivity: Chronic Methadone Use vs Healthy Controls
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Figure 4 
 
Study name Outcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Tolomeo et al 2016 SOC (5 move) 4.667 0.390 0.152 3.903 5.431 11.972 0.000
Clark et al 2006 BIS non planning 1.132 0.270 0.073 0.602 1.662 4.184 0.000
Darke et al 2000 ROCFT copy 0.666 0.265 0.070 0.147 1.186 2.512 0.012
Ersche et al 2006 TOL  (4-6 moves) 0.641 0.279 0.078 0.094 1.187 2.295 0.022
McDonald et al 2012 ROCFT copy 0.476 0.177 0.031 0.129 0.824 2.687 0.007
Ornstein et al 2000 TOL % correct 1.179 0.327 0.107 0.538 1.819 3.608 0.000
Wang et al 2014 AM trial completed 0.624 0.273 0.075 0.088 1.159 2.283 0.022
1.308 0.421 0.177 0.483 2.134 3.106 0.002
-4.00 -2.00 0.00 2.00 4.00
Favours Methadone Favours Healthy Control
Non Planning Impulsivity: Chronic Methadone Use vs Healthy Control
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Figure 5 
 
Study name Outcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Tolomeo et al 2016 IED EDS errors 0.769 0.209 0.044 0.359 1.180 3.673 0.000
Darke et al 2000 COWAT total 0.571 0.263 0.069 0.055 1.087 2.168 0.030
Ersche et al 2006 IED EDS mean errors 0.228 0.273 0.075 -0.307 0.764 0.836 0.403
Gupta et al 2014 CLFT total correct 0.229 0.101 0.010 0.031 0.427 2.263 0.024
McDonald et al 2012 COWAT total 0.404 0.177 0.031 0.058 0.751 2.289 0.022
Mintzer et al 2005 TMT- B total time 0.833 0.335 0.112 0.176 1.489 2.487 0.013
Ornstein et al 2000 IED perseveration 0.430 0.305 0.093 -0.168 1.027 1.408 0.159
Prosser et al 2006 COWAT total 0.750 0.272 0.074 0.218 1.283 2.762 0.006
Rotterham-Fuller et al 2004WCST perseveration errors 0.104 0.472 0.223 -0.820 1.029 0.221 0.825
Soyka et al 2008 TMT-B 0.740 0.298 0.089 0.155 1.325 2.479 0.013
Wang et al 2014 COWAT word generation 0.336 0.269 0.072 -0.191 0.863 1.251 0.211
Yates et al 2009 WCST perseverative errors 0.651 0.242 0.059 0.177 1.125 2.691 0.007
0.458 0.071 0.005 0.318 0.599 6.412 0.000
-4.00 -2.00 0.00 2.00 4.00
Favours Methadone Favours Healthy Control
Cognitive Flexibility: Chronic Methadone Use vs Healthy Control
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Figure 6 
Study name Outcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mintzer et al 2005 WAIS Digit Symbol 0.985 0.340 0.116 0.318 1.651 2.896 0.004
Wang et al 2014 TOVA 0.194 0.268 0.072 -0.331 0.718 0.723 0.469
Lin et al 2012 WAIS Digit Symbol 1.108 0.305 0.093 0.511 1.705 3.638 0.000
Darke et al 2000 WAIS Digit Symbol 1.425 0.289 0.084 0.858 1.991 4.928 0.000
Gupta et al 2014 WAIS Digit Symbol 0.044 0.101 0.010 -0.154 0.241 0.432 0.665
Yates et al 2009 TMT-A 0.360 0.238 0.057 -0.106 0.826 1.513 0.130
Soyka et al 2008 TMT-A 0.757 0.299 0.089 0.171 1.342 2.532 0.011
McDonald et al 2012 WAIS Digit Symbol 1.034 0.185 0.034 0.671 1.397 5.579 0.000
0.713 0.206 0.043 0.308 1.118 3.454 0.001
-8.00 -4.00 0.00 4.00 8.00
Favours Methadone Favours Healthy Control
Attention: Chronic Methadone Use vs Healthy Controls
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Figure 7 
Study name Outcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Baldacchino et al 2014PRM correct 0.782 0.275 0.076 0.243 1.320 2.844 0.004
Darke et al 2000 PAL-I 0.940 0.272 0.074 0.407 1.474 3.456 0.001
Ersche et al 2006 PRM immediate 0.641 0.279 0.078 0.094 1.188 2.297 0.022
Gupta et al 2014 HVLT total learning 0.233 0.101 0.010 0.034 0.431 2.297 0.022
Lin et al 2012 WAIS digit span forwards 0.599 0.290 0.084 0.031 1.168 2.066 0.039
McDonald et al 2012 WAIS digit span forwards 0.748 0.181 0.033 0.394 1.102 4.144 0.000
Mintzer et al 2005 2BT response bias 0.000 0.321 0.103 -0.630 0.630 0.000 1.000
Ornstein et al 2000 PRM % correct 0.800 0.313 0.098 0.186 1.414 2.552 0.011
Prosser et al 2006 BVRT errors 0.968 0.278 0.077 0.424 1.512 3.488 0.000
Soyka et al 2008 AVLT learning 1.349 0.320 0.102 0.722 1.976 4.218 0.000
Wang et al 2014 WAIS digit span forwards 0.313 0.269 0.072 -0.214 0.839 1.164 0.244
Yates et al 2009 WMS immediate 1.084 0.252 0.063 0.591 1.578 4.304 0.000
0.686 0.118 0.014 0.454 0.917 5.812 0.000
-4.00 -2.00 0.00 2.00 4.00
Favours Methadone Favours Healthy Group
Short Term Memory: Chronic Methadone Use vs Healthy Control
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Figure 8 
Study name Outcome Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Baldacchino et al 2014 DMS total number of correct responses 1.869 0.318 0.101 1.247 2.492 5.886 0.000
Darke et al 2000 PAL-II 1.546 0.294 0.087 0.969 2.123 5.254 0.000
Ersche et al 2006 PRM delayed 0.076 0.272 0.074 -0.457 0.610 0.280 0.780
Gupta et al  2014 HVLT delayed 0.146 0.101 0.010 -0.052 0.344 1.448 0.148
Lin et al 2012 Remote Life Events 0.442 0.287 0.082 -0.121 1.005 1.539 0.124
McDonald et al 2012 PAL-II 0.678 0.180 0.032 0.326 1.030 3.775 0.000
Mintzer et al 2005 Word Memory Recognition response bias 0.195 0.322 0.104 -0.436 0.826 0.607 0.544
Wang et al 2014 RAVLT long delay 0.158 0.267 0.071 -0.366 0.681 0.589 0.556
Yates et al 2009 WMS delayed 1.140 0.254 0.064 0.643 1.637 4.495 0.000
0.676 0.201 0.040 0.282 1.069 3.368 0.001
-2.00 -1.00 0.00 1.00 2.00
Favours Methadone Favours Healthy Control
LongTerm Memory: Chronic Methadone Use vs Healthy Controls
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Figure 9 
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Davis et al 2002 COWAT total 1.088 0.385 0.148 0.333 1.843 2.826 0.005
Liao et al 2014 SSRT stop signal 1.436 0.149 0.022 1.143 1.729 9.616 0.000
McDonald et al 2012COWAT total 0.253 0.176 0.031 -0.091 0.598 1.441 0.149
Mintzer et al 2005 TMT-B total time 0.078 0.325 0.106 -0.559 0.715 0.240 0.810
Tolomeo et al 2016IED EDS errors 2.797 0.329 0.108 2.152 3.441 8.510 0.000
1.121 0.432 0.187 0.274 1.969 2.593 0.010
-2.00 -1.00 0.00 1.00 2.00
Favours Methadone Favours Abstinent Group
Cognitive Flexibility: Chronic Methadone Use vs Abstinent
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Figure 10 
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Davis et al 2002 TEA accuracy 0.346 0.362 0.131 -0.363 1.056 0.956 0.339
Gritz et al 1975 SRRT 2.208 0.567 0.322 1.096 3.320 3.892 0.000
McDonald et al 2012WAIS digit symbol 0.414 0.177 0.031 0.067 0.760 2.341 0.019
Mintzer et al 2005 WIAS digit symbol 0.495 0.330 0.109 -0.152 1.141 1.501 0.133
0.701 0.292 0.085 0.128 1.274 2.399 0.016
-4.00 -2.00 0.00 2.00 4.00
Favours Methadone Favours Abstinent Group
Attention: Chronic Methadone Use vs Abstinent
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Figure 11 
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Davis et al 2002 AMIPB immediate story recall 0.248 0.361 0.130 -0.459 0.955 0.688 0.492
Gritz et al 1975 VLT 1.163 0.484 0.234 0.215 2.110 2.405 0.016
McDonald et al 2012PAL-I 0.322 0.176 0.031 -0.023 0.667 1.829 0.067
Mintzer et al 2005 2BT response bias 0.024 0.325 0.106 -0.613 0.661 0.073 0.942
Prosser et al 2006 BVRT errors 0.570 0.273 0.074 0.035 1.104 2.088 0.037
0.381 0.135 0.018 0.116 0.646 2.818 0.005
-4.00 -2.00 0.00 2.00 4.00
Favours Methadone Favours Abstinent Group
Short Term Memory Chronic Methadone Use vs Abstinent
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Figure 12 
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Davis et al 2002 AMIPB  delayed story recall 0.173 0.360 0.130 -0.533 0.878 0.480 0.631
Gritz et al 1975 WPAT total 1.228 0.488 0.238 0.272 2.183 2.519 0.012
McDonald et al 2012PAL-II 0.216 0.175 0.031 -0.128 0.560 1.229 0.219
Mintzer et al 2005 Word Memory  response bias 0.357 0.327 0.107 -0.285 0.999 1.091 0.275
0.352 0.174 0.030 0.011 0.694 2.022 0.043
-4.00 -2.00 0.00 2.00 4.00
Favours Methadone Favours Abstinent Group
LongTerm Memory: Chronic Methadone Use vs Abstinent
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Tables 
Table 1: Executive Functions 
Domain Subtypes Other names Definition Tests 
 
 
 
 
 
 
IMPULSIVITY 
Cognitive Impulsivity Delay discounting or urgency Ability to opt for larger delayed rewards over smaller 
more immediate rewards 
 
Reflection Impulsivity  Decision-making under ambiguity IGT, MFFT, BIS, DDT, IST 
Risk taking  Decision-making under risk CGT, IGT, RDMT, GDT 
Non-planning Impulsivity 
 
 
Reasoning, Strategic Planning  and Problem 
Solving, Lack of pre-meditation 
Ability to think ahead and actively search for an 
appropriate solution.  
TOL, SOC, ROCFT, PMT, TOH 
WAIS –R/III (Block Design, 
Matrix Reasoning), SSP, AM, 
BADS 
Motor Impulsivity Inhibitory Control Ability to suppress emotional, cognitive and 
behavioural responses 
 
Behavioural Inhibition Motor Response Inhibition Process requires to stop a planned movement AGN, SS, Go/NoGo  
Cognitive Inhibition Focused Attention Process required to suppress a salient but conflicting 
stimulus while identifying  less salient ones 
ST 
     
COGNITIVE 
FLEXIBILITY 
 Cognitive Rigidity Ability to shift avenues of thought and action in order 
to perceive process and respond to situations in 
different ways  
 
 Reactive Flexibility  Perseveration or shifting of perceptual set Ability to realign a behavioural predisposition to 
altered contingencies 
WCST, IED, FAT 
TMT-B, SCT, MCST, BADS (Rule 
Shift Card, Modified Six 
Elements), CBT 
 Spontaneous Flexibility  Verbal and non verbal fluency Requires the intrinsic generation of responses or 
alternatives 
COWAT, FAS, VFT, RFFT, WAIS- 
R/III (Similarities), CLFT, HSCT, 
RWFT 
     
ATTENTION Deployment  Arousal/Alertness  DSST 
  Focused and Selected Attention/Vigilance Ability to reject irrelevant information while attending 
to relevant input  
TMT-A, TEA, ST, AVT, RT, SSRT, 
DR2,Q1 
  Sustained Attention Readiness to detect rarely and unpredictable occurring 
signals over prolonged periods of time 
PASAT, TOVA, TEA, CPT,FTT, 
ACT, SRT 
 Capacity/Encoding or Data 
Processing  
 Ability for individuals to hold information in mind and 
process OR need to process tasks simultaneously 
CVLT, RAVLT, DSST,WAIS-R/III 
(Digit Symbol), FTT 
ACT= Attentional Capture Task, AGN= Affective Go-NoGo (CANTAB) , AM= Austine Maze,  BADS= Behavioural Assessment of Dysexecutive Syndrome , BIS= Barratt Impulsiveness Scale , BLC= Big Little Circle (CANTAB), 
CBT= Corsi Block Test, CGT= Cambridge Gambling Task (CANTAB), CLFT= Category and Letter Fluency Test, CPT= Continuous Performance Test, COWAT= Controlled Oral Word Association Test, CTT= Colour Trail Test, 
CVLT =California Verbal Learning Test, DDT= Delay Discounting Test, DSST= Digit Symbol Substitution Test, FAS= Phonological Fluency Test, FTT= Finger Tapping Test, GDT= Game and Dice Test, HSCT= Hayling 
Sentence Completion Test, IED= Intra/Extra-Dimensional Set Shifting Task (CANTAB), IST= Information Sampling Test, IGT= Iowa Gambling Task, MFFT= Matching Familiar Figures, MCST= Maudsley Card Sorting Test, 
PASAT= Paced Auditory Serial Addition Task , PMT= Proteus Maze Test, RAVLT= Rey Auditory Verbal Learning Test ,RDMT= Rogers Decision Making Task, ROCFT= Rey-Osterreith Complex Figure Test, RT= Reaction 
Time, RWFT= Regensburger Word Fluency Test,  SCT= Logan Stop Change Task,  SOC= Stockings of Cambridge (CANTAB), SSP= Spatial Span (CANTAB), SS= Stop Signal, SRT= Serial Reaction Time, SWM= Spatial 
Working Memory (CANTAB), ST= Stroop Test, TEA= Test of Everyday Attention, TMT= Trail Making Test, TOH= Tower of Hanoi, TOL=Tower of London (CANTAB), TOVA= Test of Variables of Attention, VFT= Benton 
Verbal Fluency Test, WCST= Wisconsin Card Sorting Test, WAIS-R/III= Wechsler Adult Intelligence Scale -Revised/Third Edition. Act React Test Systems (ART 90/2020): FAT= Test of Attentional Flexibility, DR2= Simple 
Choice Reaction, Q1= Attention under Monotonous Circumstances, MAT=Matrices for Intelligence Test, RST3= Multiple Choice under Stress, LL5= Labyrinth of Lines to Measure Visual Structuring Performance. 
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Table 2: Memory and Learning 
 
Domain Subtypes Other names Definition Test 
 
 
 
Short Term 
Memory 
 
 
 
 
Immediate 
Memory 
 
Verbal Working Memory 
 
 
Reproduction, recognition or recall of 
information directly or sometime after 
presentation 
 
LMT, RAVLT, CVLT,WAIS-III/R (Digit Span, 
Letter Numbering), VRM, WMS-R/III 
(Prose Passage, Associate Learning), 
WRM, GNT, DFDBT, 2BT, HVLT-R, WCST 
(Working Memory Index), VLT, WPAT 
Non Verbal (Visuospatial) Working 
Memory 
Allow information to be evaluated and perhaps 
stored longer through rehearsal and coding 
SWM, SSP. DMS, PRM, PAL, BVRT, PAL, 
SRM,.WMS-R/III, ROCFT, PASAT, WAIS-
III/R (Matrix Reasoning),BVMT-R, CCDT, 
3D-BCM, CBT, WMS-R/III (Spatial Span) 
     
 
 
 
 
Long Term 
Memory 
 
Explicit 
(Declarative) 
Memory 
Autobiographical, Episodic or  Event 
Memory 
 
 
Records details salient to individual’s life. 
Needs conscious thinking 
‘Knowing that’ 
 
SOMT, WSLT, BVRT, CVLT, RAVLT, RCFT,  
WMS-R, WAIS-III/R (Vocabulary) 
Semantic Memory 
 
Meaning of words and concepts or 
propositional knowledge (facts) 
RCFT, RRLET, SAVF,GNT , WMS-R, RBMT 
Implicit (Non 
Declarative) or 
Procedural 
Memory 
Motor skill training and  
Priming or classical conditioning  
Does not need conscious thinking ‘Knowing 
how’ 
                                                           
BVMT-R= Brief Visuospatial Memory Test-Revised, BVRT=Benton Visual Retention Test, CBT= Corsi Block Test, CCDT= Colour Change Detection Tas , COWAT= Controlled Oral Word Association Test, CVLT= California 
Verbal Learning Test, DFDBT= Digit Forward and Digit Backwards Test, DMS=Delayed Matching to Sample (CANTAB), GNT=Graded Name Test (CANTAB), HVLT-R= Hopkins Verbal Learning Test-Revised, LMT= Logical 
Memory Test, SRM=Spatial Recognition Memory (CANTAB),  PAL= Paired Associate Learning (CANTAB), PASAT= Paced Auditory Serial Addition Task, PRM= Pattern Recognition Memory (CANTAB), RAVLT= Rey 
Auditory Verbal Learning Test, RBMT= Rivermead  Behavioural Memory Test, ROCFT= Rey Osterreith Complex Figure Test, RRLET= Remote and Recent Life Event Test, SAVF= Semantic Association of Verbal Fluency , 
SOMT= Six Object Memory Test, SWM=Spatial Working Memory (CANTAB), SSP=Spatial Span (CANTAB), 2BT= Two Back Test, 3D-BCM= Three Dimensional Block Consititution Model, VLT= Verbal Learning Task, VRM= 
Verbal Recognition Memory (CANTAB), WAIS-R/III= Wechsler Adult Intelligence Scale-Revised/ 3rd Edition, WMS-R/III= Wechsler Memory Scale-Revised/3rd Edition, WPAT= Wechsler Paired Associate Test, WRM= Word 
Recognition Memory, WSLT= Word Sequence Learning Test. 
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Table 3a: Specific Characteristics of Selected Studies Comparing Chronic Methadone Users with Healthy Participants (n=21). 
                                                                                  Methadone Group             Healthy Participants  
    Study 
Country 
 
Qual   N 
Age  
(yrs) 
Gender  
M:F 
Education 
(yrs) 
Mean 
IQ (sd) 
Mean 
/Min*1 
opioid 
use  in 
yrs 
Mean 
methadone  
use in yrs 
Mean daily  
methadone  
dose (mg) 
 N 
Age 
(yrs) 
 
Education        
(yrs)  
 Mean   
IQ  (sd) 
Neuropsychological measures  
Ornstein et al 
(2000) 
UK 
England 
Mod 22 33.3 1:0 11.9  
108.9 
(9.4) 
11.6  1.4 43.0 22 32.1 15 
112.8 
(8.5) 
NART(IQ), SRM, SWM, PRM,TOL, VFT, IED 
Darke et al  
(2000) 
Australia Mod 30 35.8 3:2 11.2  
91.5 
(10.4) 
5.0*1 5.0 78.6 30 35.2 11.7 
92.6 
(11.1) 
WAIS-II (IQ), WMS-R (PAL I & II and VR I& II)), 
CVLT,ROCFT, COWAT, WCST, WAIS-II  
(Digit Span & Symbol) 
Rotherham-
Fuller et al  
(2004) 
      US  
  California 
Mod 18 41.7 n/a 11.8  
83.8 
(9.7) 
0.5*1 0.5 61.6 
19 
 
37.0 13.6 
90.1 
(13.2) 
SILS (IQ), WCST, GT 
Schindler et 
al (2004) 
Austria Mod 15  25.8 3:2 11.5 n/a 4.3 1.6 45.7 56 26.0 n/a n/a LL5, FAT, DR2,Q1,RST3 
Mintzer et  
al (2005) 
US 
Baltimore 
Mod 18 37.6 2:1 11.2  
87.4 
(2.7) 
15.3  3.8 67.2 
21 
 
34.9 12.1 
94 
(2.8) 
SILS (IQ), 2BT, TMT (A&B), DSST,  IGT  
Clark et al 
(2006) 
UK 
England 
Mod 40 34.0 4:1 n/a 
112.8 
(5.9) 
11.0 n/a 42.8 
26 
 
34.4 n/a 
114.1 
(7.2) 
NART(IQ), IST, BIS 
Ersche et  
al 
(2005/2006) 
UK 
England 
Mod 27 33.8 4:1 n/a 
113 .4 
(6.5) 
10.8 n/a 45.2 
27 
 
35.1 n/a 
114.4 
(6.5) 
NART(IQ), PAL, PRM, TOL, IED, CGT 
Pirastu et  
al (2006) 
Italy Mod 30  34.0 
     2 
females 
8.3  
85 
(1.8) 
15.5 8.3 66.0 21 34.0 10.9 
104  
(3.4) 
WAIS-III (IQ),BVRT, WCST, IGT 
Prosser et  
al (2006) 
      US  
  New York 
Mod 29 37.9 4:1 13.0  
8.05 
(2.2) 
15.1  6.4 73.8 
29 
 
 
34.0 15.5 
12.2 
(3.4) 
WAIS-III (IQ), BVRT, COWAT, ST,  
Soyka et al 
(2008)* 
Germany Mod 
 
24 
 
32.0     2:1. 10.0 n/a 11.0 0.4 56.0 24 32.0 11.0 n/a AVLT, RWT,TMT (A&B), DR2 
Yates (2009)   New 
Zealand 
Mod 29 36.5 2.2:1.5       11.9 111 
(5.3) 
12.9 6.9 86.7 47 24.5 13.7 113.5 
(5.7) 
NART(IQ), WMS (Story Recall), TMT (A&B),  
ST, WCST 
Fadardi et  
al (2010) 
   Iran Mod 53 36.6     1:0       10.3 n/a 4.0*1 4.0 75.0 71 26.6 14.2 n/a ST 
Yin et al  
(2012) 
 China   
Huainan 
Mod 42 33.9     1:0        8.9 n/a 8.7 1.6 45.3 31 33.5 9.8 n/a IGT 
Lin et al  
(2012) 
Taiwan Mod 27 37.0      1 
female 
      10.3 n/a 13.9 1.7 36.0 23 34.0 15.4 n/a SOMT, WSLT, BVRT, SAVF, RRLET, WAIS-R  
(Digit Span & Symbol), Halstead Reitan Test 
(Proverbs),  3D-BCM 
McDonald  
et al (2012) 
Australia Mod 94 38.0   1.8:1        9.8 98.3 
(10.2) 
18.8 6.1 83.0 50 35.8 11.2 105.9 
(6.9) 
WTAR(IQ) , WMS-III (Story Recall), WAIS-III  
(Digit Span & Symbol), COWAT, HSCT,  
ROCFT, BADS, RAVLT 
  
 51 
Anderson  
et al (2013)* 
     US        
Baltimore 
Mod 17 44.4     9:8     11.5 n/a 1.7*1 1.7 77.9 17 42.9 14.7 n/a BIS, CCDT,ACT 
Gupta et al 
(2014) 
  China              
Yunnan 
Mod 195 35.8   1.8:1      9.8 n/a 14.0 0.7 n/a 198 34.6 9.9 n/a WMS-III (Spatial Span), CLFT, WAIS-III   
(Digit Symbol & Span), TMT (A), CTT, HVLT-R, 
BVMT-R, PASAT, Halstead Reitan Test 
(Category), ST 
Liao et al 
(2014) 
  Taiwan Mod 65 40.2    1:0      8.6 n/a 14.3 0.5 45.0 64 36.8 9.3 n/a SSRT, SRT 
Baldacchino 
et al  (2014) 
    UK    
Scotland 
 S 29 27.3    1:0     10.6 108.9 
(7.6) 
8.8 1.3 55.8 28 24.1 15.4 118.3 
(5.1) 
NART(IQ), CGT, AGN,SOC ,IED, PAL, SRM, PRM, 
SWM, SSP, DMS 
Wang et al 
(2014) 
  New 
Zealand 
Mod 32 39.4 1.6:1.3     12.1 45.6 
(6.7) 
10.0 7.3 70.9 25 36.1 13.9 44.3(7) 
 
SpTW/SCOLP (IQ), RAVLT, WAIS-III (Digit 
Span), CBT, CRT, FTT, TOVA, ST,TMT (A&B), 
COWAT, AM 
Tolomeo et 
al 2016 
UK  S 48 30.2 1:0      10.6 103 
(9.4) 
9.2 1.4 66.6 50 28.0 15.4 117.9 
(6.0) 
NART, SOC, CGT, IED 
 
MMP= Methadone Maintained Programme, n/a = not available, R/L Hand= Right or Left Handed, M= Male; F=Female, yrs= years; Qual= Quality of Study, Mod=Moderate, S= Strong, W=Weak 
*= Longitudinal Studies,  Min *1 = Minimum years of opioid use (when mean opioid use is not provided in the manuscript) 
 
ACT= Attentional Capture Task, AVLT= Auditory Verbal Learning Test, AM= Austine Maze, BADS= Behavioural Assessment of Dysexecutive Syndrome, BIS= Barratt Impulsiveness Scale , BVMT-R= Brief Visuospatial 
Memory Test-Revised, BVRT= Benton Visual Retention Test,  CBT= Corsi Block Test, CCDT= Colour Change Detection Task, CLFT= Category and Letter Fluency Test, COWAT= Controlled Oral Word Association Test, CRT= 
Choice Reaction Time, CTT= Colour Trail Test , CVLT= California Verbal Learning Test, FTT= Finger Tapping Test, GT=Gambling Task, HSCT= Hayling Sentence Completion Test, HVLT-R= Hopkins Verbal Learning Test-
Revised, IGT= Iowa Gambling Task, IST=Information Sampling Task, NART= National Adult Reading Test , PASAT= Paced Auditory Serial Addition Test, RAVLT= Rey Auditory Verbal Learning Test, ROCFT= Rey Osterreith 
Complex Figure Test, RRLET= Remote and Recent Life Event Test, RWT= Regensburger Word Fluency Test,), SAVF= Semantic Association of Verbal Fluency, SCOLP (SpTW)= Speed and Capacity of Language Processing 
(Spot the Word- % accuracy), SILS= Shipley Institute of Living Skills, SOMT= Six Object Memory Test, ST= Stroop Test, SSRT= Stop Signal Reaction Time, TOVA= Test of Variables of Attention, 3D-BCM= Three 
Dimensional Block Consititution Model, 2BT= Two Back Task, VFT= Verbal Fluency Test, WAIS- III/II= Wechsler Adult  Intelligence Scale- 3rd/2nd  Edition,  WCST= Wisconsin Card Sorting Test ,WMS-R/III= Wechsler 
Memory Scale- Revised/3rd Edition, WSLT= Word Sequence Learning Test, WTAR= Wechsler Test of Adult Reading Skills, CANTAB: PAL= Paired Associate Learning, PRM= Pattern Recognition Memory, SRM= Spatial 
Recognition Memory, SWM= Spatial Working Memory, SOC = Stockings of Cambridge, TOL= Tower of London,  IED= Intra/Extra-Dimensional Set Shifting, CGT= Cambridge Gambling Task, SSP= Spatial Span,DMS= 
Delayed Matching to Sample; Halstead Reitan Neuropsychological Test Battery: TMT= Trail Making Test, Proverbs, Category Test, Act React Test Systems (ART 90/2020): FAT= Test of Attentional Flexibility, DR2= 
Simple Choice Reaction, Q1= Attention under Monotonous Circumstances, RST3= Multiple Choice under Stress, LL5= Labyrinth of Lines to Measure Visual Structuring Performance. 
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Table 3b: Specific Characteristics of Selected Studies Comparing Chronic Methadone Users with Short Term Abstinent Individuals (n=7). 
                                                Methadone Group                                       Abstinent Group  
    Study 
Country 
 
Qual   N 
Age  
(yrs) 
Gen
der  
M:F 
Educ
ation 
(yrs) 
Mean  
IQ (sd) 
Mean 
opioid 
use 
(yrs) 
Mean 
methadone  
use (yrs) 
Mean daily  
methadone  
dose (mg) 
 N 
Age 
(yrs) 
 
Education        
(yrs)  
   
Mean 
IQ (sd) 
Mean 
opioid 
use 
(yrs) 
 Period of 
abstinence 
    (yrs) 
 
Neuropsychological measures  
Gritz et  
al (1975)61 
       US 
California 
 W 10 31.0 1:0 11.4 n/a 11.5 0.4 65.0 10 25.0 15.0 n/a      5 0.3 DSST, DFDBT, SRTT, VLT, WPAT 
Davis et  
al (2002) 
UK 
England 
 W 15 34.0 n/a 11.4 
101  
(9.5) 
14.6 0.6 32.5 
16 
 
31.0 10.9 
99  
(9.9) 
  11.5 0.5 
WAIS-II (IQ), AMIPB, TEA, WAIS-II  
(Block Design, Object Assembly),  
COWAT 
Mintzer et  
al (2005) 
US 
Baltimore 
Mod 18 37.6 2:1 11.2  
87.4 
(2.7) 
15.3 3.8 67.2 
20 
 
40.2 11.2 
89.8  
(2.1) 
  16.9 0.8 
SILS (IQ), 2BT, TMT (A&B), DSST,  IGT, 
ST  
Prosser  
et al (2006) 
       US  
New York 
Mod 29 37.9 4:1 13.0  
8.1 
(2.2) 
15.1 6.4  73.0 
27 
 
 
42.6 11.8 
8.6 
(3.1) 
  13.7 0.9 
WAIS-III (IQ), BVRT, COWAT,  
ST 
McDonald  
et al (2012) 
Australia 
Mod 
94 38.0   
1.8:1 
         
9.8 
98.3 
(10.2) 
18.8 
        6.1 83.0 50 
34.1 10.3 
100.7 
(9.2) 
              
20.6 
        0.2 WTAR(IQ), WMS-III (Story Telling),  
WAIS-III (Digit span & Symbol),  
COWAT, HSCT, ROCFT, RAVLT  
Liao et al 
(2014) 
 Taiwan 
Mod 
65 40.2  1:0 8.6 
n/a 14.3 
        0.5 45.0 264 
36.4 9.2 n/a 
  7.2        0.3 SSRT, SRT 
Tolomeo et 
al (2016) 
     UK 
Scotland 
  S 
48 30.2 1:0 10.6 103 
(9.4) 
9.2 
        1.4 66.6 25 
36.6 10.6 
111.3 
(2.1) 
  3.8        0.5 NART(IQ), CGT, SOC, IED 
MMP= Methadone Maintained Programme, n/a = not available, R/L Hand= Right or Left Handed, M= Male, F=Female, yrs= years, Qual= Quality of the Study; S=Strong, Mod=Moderate, W=Weak 
 
AMIPB = Adult Memory and Information Processing Battery, BADS= Behavioural Assessment of Dysexecutive Syndrome , BIS= Barratt Impulsiveness Scale, CDT= Clock Drawing Test, COWAT= Controlled Oral Word 
Association Test, DSST=Digit Symbol Substitution Test, DFDBT= Digits Forward and Digits Backward Test, HSCT= Hayling Sentence Completion Test, IGT= Iowa Gambling Task, NART= National Adult Reading Test , 
RAVLT= Rey Auditory Verbal Learning Test , ROCFT= Rey Osterreith Complex Figure Test, ST= Stroop Test , SSRT= Stop Signal Reaction Time,  SpTW= Spot the Word - % accuracy, SRTT= Serial Reaction Time Task, SRT= 
Simple Reaction Time, TEA= Test of Everyday Attention, VLT= Verbal Learning Test, WAIS- III/II= Wechsler Adult Intelligence Scale- 3rd/2nd  Edition, WMS-R/III= Wechsler Memory Scale-Revised/ 3rd Edition , WPAT= 
Wechsler Paired Associate Test, WTAR= Wechsler Test of Adult Reading Skills, CANTAB:  PAL= Paired Associate Learning, PRM= Pattern Recognition Memory, SOC = Stockings of Cambridge, IED= Intra/Extra-
Dimensional Set Shifting, CGT= Cambridge Gambling Task, Halstead Reitan Neuropsychological Test Battery: TMT= Trail Making Test.  
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Table 4a: Pooled Effect Sizes for Individual Neuropsychological Domains in Chronic Methadone Users Compared to Healthy Participants. 
 
 
   Effect  Size and 95% Confidence 
Interval 
Test of null (2 
tail) 
Heterogeneity 
Publication 
Bias 
Neuropsychological 
Domains* 
N 1 Studies 
2 
Effect Size3 SE4 Lower   
Limit 5 
Upper   
Limit 6 
Z 7 
P for Z 
8 
Q 9 
p for Q  
10 
I² 11 
Fail safe N 
12 
Cognitive Impulsivity  214 7 0.89 0.32 0.26 1.53 2.8 0.006 51.16 0.00 88.27 79 
Motor Impulsivity 490 9 0.41 0.09 0.23 0.59 4.5 0.001 14.14 0.08 43.42 80 
Non Planning Impulsivity 293 7 1.38 0.42 0.48 2.13 3.1 0.002 102.76 0.00 94.16        221 
Cognitive Flexibility 557 12 0.46 0.07 0.32 0.60 6.4 0.001 12.76 0.31 13.82 145 
Attention 467 8 0.71 0.21 0.31 1.12 3.5 0.001 48.77 0.00 85.03 120 
Short Term Memory  556 12 0.67 0.12 0.45 0.92 5.8 0.001   31.30 0.001 64.85        269 
Long Term Memory 481 9 0.68 0.20 0.28 1.07 3.4 0.001 55.55 0.00 85.60        140 
1=Total number of  methadone subjects 2= Number of studies used to calculate effect size, 3= Cohen’s d effect size, 4= Standard Error ,5= Lower limit of the 95% confidence interval for the effect size, 6= Upper limit of 
the 95% confidence interval for the effect size, 7= One sample Z Statistic, 8= Probability that Z Statistics is significantly different than 0 9= Q statistic, 10= Probability that Q statistics significantly different than 0, 11= I² 
statistics, 12= Classic  Fail safe N, * All neuropsychological domains with random effects model employed. 
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Table 4b: Pooled Effect Sizes for Individual Neuropsychological Domains in Chronic Methadone Users Compared to the Abstinent Group. 
 
   Effect  Size and 95% Confidence 
Interval 
Test of null (2 
tail) 
Heterogeneity 
Publication 
Bias 
Neuropsychological 
Domains* 
N 1 Studies 
2 
Effect Size3 SE4 Lower   
Limit 5 
Upper   
Limit 6 
Z 7 
p for Z 
8 
Q 9 
p for Q  
10 
I² 11 
Fail safe N 
12 
Cognitive Impulsivity  66 2 0.34 0.19 -0.04 0.72 1.7 0.08 0.54 0.46 0.00 N/P 
Motor Impulsivity 112 3 0.14 0.12 -0.08 0.37 1.2 0.21 0.46 0.79 0.00 0 
Non Planning Impulsivity 142 2 0.75 0.59 -0.41 1.91 1.3 0.21 14.03 0.00 92.87         N/P 
Cognitive Flexibility 240 5 1.12 0.43 0.27 1.70 2.6 0.01 64.44 0.00 93.79 129 
Attention 137 4 0.70 0.29 0.13 1.27 2.4 0.01 9.45 0.02 68.25 16 
Short Term Memory  166 5 0.38 0.14 0.12 0.65 2.8 0.005 4.55 0.34 12.01 9 
Long Term Memory 137 4 0.35 0.17 0.01 0.69 2.0 0.04 3.99 0.26 24.98          4 
1=Total number of  methadone subjects 2= Number of studies used to calculate effect size, 3= Cohen’s d effect size, 4= Standard Error,5= Lower limit of the 95% confidence interval for the effect size, 6= Upper limit of the 
95% confidence interval for the effect size, 7= One sample Z Statistic, 8= Probability that Z Statistics is significantly different than 0 9= Q statistic, 10= Probability that Q statistics significantly different than 0, 11= I² 
statistics, 12= Classic  Fail safe N, * All neuropsychological domains with random effects model employed. 
N/P= one needs at least 3 studies to determine publication bias 
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Tables 5a and 5b: Subgroup Analysis: Meta-Regression of Chronic Methadone Group for Age in Years and (a) Cognitive Flexibility and (b) 
Short Term Memory. 
 
Table 5a: 
Regression of Age (yrs) and Cognitive Flexibility:Methadone  on Std diff in means
Age (yrs) and Cognitive Flexibility:Methadone 
S
td
 d
if
f 
in
 m
e
a
n
s
25.86 27.59 29.32 31.04 32.77 34.50 36.23 37.96 39.68 41.41 43.14
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
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Table 5b: 
Regression of Age(yrs) and Short Term Memory: Methadone on Std diff in means
Age(yrs) and Short Term Memory: Methadone
S
td
 d
if
f 
in
 m
e
a
n
s
26.23 27.51 28.80 30.08 31.37 32.65 33.93 35.22 36.50 37.79 39.07
2.00
1.80
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
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Online supplementary information 
SFigure 1 
 
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mintzer et al 2005 IGT netscore 0.144 0.325 0.106 -0.494 0.781 0.441 0.659
Tolomeo et al 2016CGT overall choice 0.442 0.240 0.058 -0.029 0.913 1.838 0.066
0.337 0.193 0.037 -0.042 0.716 1.740 0.082
-1.00 -0.50 0.00 0.50 1.00
Favours Methadone Favours Abstinent Group
Cognitive Impulsivity: Chronic Methadone Use vs Abstinent
 
  
 58 
SFigure 2 
Study name Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Liao et al 2014 SSRT post error slowing 0.122 0.139 0.019 -0.150 0.393 0.880 0.379
Mintzer et al 2005 ST correct responses 0.035 0.325 0.106 -0.602 0.672 0.107 0.915
Prosser et al 2006ST interference score 0.297 0.269 0.072 -0.230 0.824 1.103 0.270
0.143 0.115 0.013 -0.083 0.369 1.242 0.214
-1.00 -0.50 0.00 0.50 1.00
Favours Methadone Favours Abstinent Group
Motor Impulsivity: Chronic Methadone Use vs Abstinent
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SFigure 3 
Study name Subgroup within study Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
McDonald et al McDonald et al 2012 ROCFT 0.174 0.175 0.031 -0.169 0.518 0.994 0.320
Tolomeo et al 2016 SOC (5 moves) 1.355 0.262 0.069 0.842 1.869 5.173 0.000
0.749 0.590 0.348 -0.408 1.905 1.269 0.205
-2.00 -1.00 0.00 1.00 2.00
Favours Methadone Favours Abstinent Group
Non Planing Impulsivity: Chronic Methadone Use vs Abstinent
 
